Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jul;9(7):413-415.
doi: 10.1016/S2213-8587(21)00116-9. Epub 2021 May 11.

Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK

Matthew J Carr  1 , Alison K Wright  2 , Lalantha Leelarathna  3 , Hood Thabit  3 , Nicola Milne  4 , Naresh Kanumilli  4 , Darren M Ashcroft  5 , Martin K Rutter  3
Affiliations
Comparative Study

Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK

Matthew J Carr et al. Lancet Diabetes Endocrinol. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

HT reports grants from Dexcom and personal fees from Eli Lilly. NK reports grants and personal fees from Novo Nordisk, Boehringer Ingelheim, Napp Pharmaceuticals, Sanofi, AstraZeneca, Nevro Corporation, and Abbott. NM reports personal fees from Napp Pharmaceuticals, Merck Sharpe & Dohme UK, AstraZeneca, Boehringer Ingelheim, OmniaMed Communications, Takeda UK, Lilly Diabetes, MyLan, MGP, Novo Nordisk, Abbott, Sanofi, Roche, and Nevro; and non-financial support from Napp Pharmaceuticals, Novo Nordisk, and Sanofi. DMA reports grants from AbbVie, Almirall, Celgene, Eli Lilly, Novartis, Janssen, UCB Pharma, and the Leo Foundation. MKR reports personal fees and non-promotional lecture fees from Novo Nordisk. MJC, AKW, and LL declare no competing interests. The study is based on data from the CPRD obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The study and use of CPRD data were approved by the Independent Scientific Advisory Committee for CPRD research (protocol number, 20_182R).

Figures

Figure
Figure
Observed and expected incident diagnoses of type 2 diabetes in England (A), HbA1c monitoring in patients with type 2 diabetes in England (B), and monthly mortality rates in people with type 2 diabetes in England (C), and in Northern Ireland, Scotland, and Wales (D) In A–D, purple lines indicate observed monthly rates, and yellow shaded regions indicate expected rates with 95% CIs; the vertical black line at March 1, 2020, separates the rates in primary care before and after the start of the COVID-19 pandemic, and x-axis markers indicate mid-months. Rates were derived by use of data from CPRD Aurum, covering 21 797 864 patients in England, and CPRD GOLD, covering 3 625 958 patients in Northern Ireland, Scotland, and Wales. CPRD=Clinical Practice Research Datalink.
See this image and copyright information in PMC

References

    1. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8:823–833. - PMC - PubMed
    1. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–822. - PMC - PubMed
    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. - PMC - PubMed
    1. Williams R, Jenkins DA, Ashcroft DM, et al. Diagnosis of physical and mental health conditions in primary care during the COVID-19 pandemic: a retrospective cohort study. Lancet Public Health. 2020;5:e543–e550. - PMC - PubMed
    1. COVID Symptom Study Has lockdown influenced our eating habits? The silent pandemic: how lockdown is affecting future health. 2020. https://covid.joinzoe.com/post/lockdown-weight-gain